FDA Tweaks Drug Codes for Easier Barcode Scans
Published Date: 3/5/2026
Rule
Summary
The FDA is updating the National Drug Code (NDC) to a clear, 12-digit format with three parts to make drug labeling easier to read and track. They’re also allowing new types of barcodes on drug packages that meet these rules. This change affects drug makers and sellers and kicks in on March 7, 2033, giving everyone plenty of time to get ready without extra costs.
Analyzed Economic Effects
8 provisions identified: 6 benefits, 2 costs, 0 mixed.
All FDA NDCs Must Be 12 Digits
FDA requires every FDA-assigned National Drug Code (NDC) to be 12 digits in a 6-4-2 format (6-digit labeler, 4-digit product, 2-digit package). This requirement takes effect March 7, 2033 and applies to existing 10-digit NDCs, which must be converted to the 12-digit format.
Industry Cost Estimate Provided
FDA estimates annualized industry costs to convert to the uniform 12-digit NDC format at about $14.64 million (range $7.64M to $22.79M) using a 7% discount rate, and about $14.90 million (range $7.79M to $23.18M) using a 3% discount rate, over a 10-year horizon.
Standardization Aims to Reduce Medication Errors
FDA says a single, uniform 12-digit NDC format should reduce errors from converting between multiple NDC formats and lower the need for extra quality control by payors and prescribers. FDA also notes the rule should help avoid potential public-health risks from medication confusion.
7-Year Delay Before Rule Starts
FDA set the rule's effective date 7 years after publication, so the 12-digit NDC requirement starts on March 7, 2033. FDA states it will use that 7-year period to engage with and help industries prepare for the change.
3-Year Post-Effective Label Transition
After the March 7, 2033 effective date, FDA allows a 3-year transition period during which it does not intend to object to continued use of pre-existing 10-digit NDCs on drug labeling for products remaining in interstate commerce. During this transition, firms should make systems that can handle both 10-digit and 12-digit formats.
Barcode Options Expanded for Labels
FDA will allow either linear or nonlinear barcodes on drug labels as long as the barcode format conforms to the rule's standards and is recognized by FDA. This gives manufacturers flexibility in choosing barcodes that meet the new requirements.
FDA Will Publish 10-to-12 Digit Mapping
FDA intends to publish a database that maps each existing 10-digit NDC to its corresponding 12-digit NDC and will keep that mapping available at least until the end of the transition period. This mapping aims to reduce conversion errors during implementation.
Converted NDCs Aren't 'New' NDCs
FDA states converting a pre-effective-date 10-digit NDC into the 12-digit format is a ministerial administrative change and is not considered assignment of a "new" NDC for registration, listing, or user-fee purposes. A drug gets a truly new NDC only if FDA assigns a new NDC after the effective date because of a product change described in regulation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-04365 — National Standards for Traffic Control Devices; the Manual on Uniform Traffic Control Devices for Streets and Highways; Revision
The Federal Highway Administration just updated the national rulebook for traffic signs and signals, called the MUTCD, fixing small errors and making things clearer for everyone on public roads. This update affects all drivers, bikers, and road workers by helping keep roads safer and easier to navigate. The new rules kick in on March 5, 2026, with no big costs, just smoother, smarter traffic control everywhere.
Next: 2026-04373 — Rules Regarding Delegation of Authority; Correction
The Federal Reserve fixed and updated its rules about who can make certain decisions on its behalf. This change adds some previously approved delegations and corrects small errors to keep things running smoothly. It affects Board members, staff, and Reserve Banks and takes effect immediately on March 5, 2026, with no new costs involved.